BRENTUXIMAB VEDOTIN PLUS CHP AS FIRST‐LINE TREATMENT IN CD30 + PERIPHERAL T‐CELL LYMPHOMAS: REAL LIFE EXPERIENCE FROM A SINGLE INSTITUTION IN SPAIN

Autor:	M. Rodriguez‐Luaces, S. Verdesoto, José-María Ribera, Anna Sureda, Jordina Rovira, J. M. Sancho Cia, Ana Oliveira, Lourdes Escoda, E. Domingo Domenech, Maite Encuentra, N. Kelleher, E. González Barca, D. Blazevic
Rok vydání:	2021
Předmět:	Oncology Cancer Research medicine.medical_specialty CD30 business.industry T cell Hematology General Medicine Peripheral First line treatment medicine.anatomical_structure Internal medicine medicine Single institution Brentuximab vedotin business medicine.drug
Zdroj:	Hematological Oncology. 39
ISSN:	1099-1069 0278-0232
DOI:	10.1002/hon.73_2881
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::591bb0d1daf11c142c3f39b00c1642fd https://doi.org/10.1002/hon.73_2881 Zobrazit plný text záznamu Plný text